| Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma A Leivas, A Pérez-Martínez, MJ Blanchard, E Martín-Clavero, ... Oncoimmunology, 2016 | 90 | 2016 |
| A phase I/II trial of interleukin-15-stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors A Pérez-Martínez, L Fernández, J Valentín, I Martínez-Romera, MD Corral, ... Cytotherapy, 2015 | 87 | 2015 |
| Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells L Fernández, JY Metais, A Escudero, M Vela, J Valentín, I Vallcorba, ... Clinical Cancer Research, 2017 | 78 | 2017 |
| Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner L Fernández Casanova, J Valentín, M Zalacain, W Leung, ... Cancer Letters, 2015 | 78 | 2015 |
| Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia firma): Vela M, C D, C P, F L, V J, G B, E A, B A, De Paz R, T J, L A, ... Cancer Letters, 2018 | 69 | 2018 |
| GMP-compliant manufacturing of NKG2D CAR memory T cells using CliniMACS Prodigy L Fernández, A Fernández, I Mirones, A Escudero, L Cardoso, M Vela, ... Frontiers Immunology 10, 2019 | 57 | 2019 |
| Influence of a moderate-intensity exercise program on early NK cell immune recovery in pediatric patients after reduced intensity hematopoietic stem cell transplantation C Chamorro-Viña, J Valentín, L Fernández, M González-Vicent, ... Integrative Cancer Therapies, 2016 | 44 | 2016 |
| The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia PC Salas, LF Casanova, MV Cuenca, D Bueno, B González, J Valentín, ... Journal Pediatric Hematology and Oncology, 2016 | 44* | 2016 |
| Unexpected High Incidence of Human Herpesvirus-6 Encephalitis after Naive T Cell-Depleted Graft of Haploidentical Stem Cell Transplantation in Pediatric Patients L Sisinni, M Gasior, R de Paz, S Querol, D Bueno, L Fernández, J Marsal, ... Biology of Blood and Marrow Transplantation, 2018 | 42 | 2018 |
| The NF-KB Inducing Kinase (NIK) modulates hematopoiesis during stress Á González Murillo, L Fernández Casanova, S Baena, G Melen, ... Stem Cells, 2015 | 33 | 2015 |
| Physical Activity in Pediatric Cancer patients with solid tumors (PAPEC): Trial rationale and design L Soares-Miranda, C Fiuza-Luces, A Lassaletta, E Santana-Sosa, ... Contemporary Clinical Trials 36 (1), 106-115, 2013 | 32 | 2013 |
| Inhibitory killer cell immunoglobulinlike receptor (iKIR) mismatches improve survival after T-cell repleted haploidentical transplantation Bastos-Oreiro M, A J, Martínez-Laperche C, F L, B E, N A, P C, ... European Journal of hematology, 2015 | 27 | 2015 |
| Hematología y oncología pediátricas LM Lopez, AL Atienza, JS Navarro, IA Aguirre, MB González, NB Gómez, ... Ergón, 2015 | 24 | 2015 |
| Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy M Vela, D Bueno, P González-Navarro, A Brito, L Fernández, A Escudero, ... Frontiers Immunology, 2019 | 20 | 2019 |
| Donor KIR Genotype Impacts on Clinical Outcome after TCell-depleted HLA matched related allogeneic transplantation for High-Risk Pediatric Leukemia Patients A Escudero, IM Romera, L Fernández, J Valentín, M González-Vicent, ... Biology of Blood and Bone Marrow Transplantation, 2018 | 19 | 2018 |
| Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy A Fernández, A Navarro-Zapata, A Escudero, N Matamala, ... Cancers, 2021 | 18 | 2021 |
| How do we manufacture clinical-grade IL-15-stimulated natural killer cell products for cancer treatment? L Fernández, A Leivas, J Valentín, A Escudero, D Corral, R De Paz, ... Transfusion, 2018 | 17 | 2018 |
| The therapeutic potential of natural killer cells to target medulloblastoma A Pérez Martínez, L Fernández Casanova, MÁ Díaz Pérez Anticancer therapy, 2016 | 17 | 2016 |
| Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural … MM Builes, MV Cuenca, JLF Soler, I Astigarraga, AP Martínez, ... BMJ open 10 (1), e029642, 2020 | 13 | 2020 |
| Aspectos inmunológicos de la leucemia mieloblástica aguda B González, D Bueno, P Rubio, S Sanromán, D Plaza, A Sastre, ... Anales de pediatría, 2015 | 12 | 2015 |
